Bioverativ's Pending Acquisition

Bioverativ raised a round of funding on January 22, 2018. Investors include Sanofi.

Bioverativ is a biopharmaceutical company focused on treatments for hemophilia and other rare blood disorders.…

Articles about Bioverativ's Pending Acquisition: